Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27551469 | 0.87 | DRD2 (0.46) | DRD2DRD3HTR2A | |
| SCHEMBL27834241 | 0.84 | DRD2 (0.38) | DRD2DRD3 | |
| SCHEMBL28605151 | 0.83 | DRD2 (0.43) | DRD2DRD3HTR2A | |
| SCHEMBL27845242 | 0.83 | DRD2 (0.43) | DRD2DRD3HTR2A | |
| SCHEMBL28966471 | 0.83 | DRD2 (0.44) | DRD2DRD3 | |
| SCHEMBL27781285 | 0.83 | DRD2 (0.44) | DRD2DRD3 | |
| SCHEMBL27527543 | 0.83 | DRD2 (0.44) | DRD2DRD3 | |
| SCHEMBL27585970 | 0.80 | — | — | |
| SCHEMBL30892887 | 0.80 | SLC6A2 (0.54) | DRD2DRD3 | |
| SCHEMBL27660036 | 0.80 | DRD2 (0.42) | DRD2DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1466605-B1 | Calcium channel blockers | NEUROMED TECH INC (CA) | 2010-03-10 | — | — | EP | disclosed |
| US-7666865-B2 | for treating pain; STROKES; ANALGESICS; do not contain substituents that are antioxidants, tropolones or coumarins | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-23 | — | — | US | disclosed |
| US-20070185105-A1 | Calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2007-08-09 | — | — | US | disclosed |
| EP-1091737-B1 | Use of 1-(3,3-diphenylpropionyl)-4-benzhydril piperazine in the treatment of pain | NEUROMED TECH INC (CA) | 2005-09-14 | — | — | EP | disclosed |
| EP-1466605-A2 | Calcium channel blockers | Neuromed Technologies Inc. (CA) | 2004-10-13 | — | — | EP | disclosed |
| US-6294533-B1 | COMPOUNDS FOR CARDIOVASCULAR DISORDERS, STROKES AND ANALGESICS | NEUORMED TECHNOLOGIES, INC. (CA) | 2001-09-25 | — | — | US | disclosed |
| EP-1091737-A2 | CALCIUM CHANNEL BLOCKERS | Neuromed Technologies Inc. (CA) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001375-A2 | CALCIUM CHANNEL BLOCKERS | NEUROMED TECHNOLOGIES, INC. (CA) | 2000-01-13 | — | — | WO | disclosed |
| US-6011035-A | LIBRARIES OF THESE COMPOUNDS CAN ALSO BE USED TO IDENTIFY ANTAGONISTS FOR OTHER TARGETS. COMPOUNDS CONTAINING BENZHYDRIL AND 6-MEMBERED HETEROCYCLIC MOIETIES | NEUROMED TECHNOLOGIES INC. (CA) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185105-A1 | Calcium channel blockers | CACNA1S, KCNN4, CACNA1C | DRD2 593/4885DRD3 415/4885HTR2A 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.